What's Happening?
Century Therapeutics has presented new preclinical data for its CNTY-813, an iPSC-derived islet replacement therapy, at the American Diabetes Association's 86th Scientific Sessions. The therapy, engineered with Allo-Evasion™ 5.0, aims to provide a functional
cure for Type 1 Diabetes (T1D) without the need for chronic immunosuppression. The data demonstrated durable glucose control in preclinical models, maintaining normoglycemia for over eight months. The therapy showed immune evasion capabilities, protecting against natural killer cell clearance and antibody-mediated phagocytosis. Century has established a Phase 1 clinical manufacturing process, with an IND submission planned for late 2026 and initial clinical data expected in 2027.
Why It's Important?
The development of CNTY-813 represents a significant advancement in T1D treatment, potentially offering a cure without the drawbacks of current therapies that require lifelong immunosuppression. This could transform the management of T1D, affecting millions of patients worldwide. The therapy's success could also pave the way for similar approaches in other autoimmune diseases, expanding the impact of iPSC-derived therapies. Century's progress in scalable manufacturing and immune evasion technology positions it as a leader in the field, potentially influencing future research and development in cell-based therapies.
What's Next?
Century Therapeutics plans to submit an Investigational New Drug application for CNTY-813 in the fourth quarter of 2026. The company anticipates initial clinical data in the second half of 2027, which will provide insights into the therapy's safety and efficacy in humans. Successful clinical trials could lead to broader patient access and potentially revolutionize T1D treatment. The biotech industry and healthcare providers will be closely monitoring these developments, as they could have far-reaching implications for the treatment of autoimmune diseases.
